Drug Profile
AAV AQP1
Alternative Names: A00X; AAV-AQP1; AAV2-hAQP1Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Kadmon Gene Therapy Holdings
- Developer MeiraGTx
- Class Gene therapies
- Mechanism of Action Aquaporin 1 replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Xerostomia
- Preclinical Sjogren's syndrome
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Xerostomia in Canada (Intraglandular)
- 03 Jul 2023 Phase-II clinical trials in Xerostomia in USA (Intraglandular) (NCT05926765)
- 28 Mar 2023 MeiraGTx completes the phase I AQUAx trial for Xerostomia in USA (Intraglandular) (NCT04043104)